Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sabin-strain inactivated poliovirus vaccine (vero cell)
- Development stage
- Unknown
- Lead developer
- Beijing Minhai Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Sabin-strain inactivated poliovirus vaccine (Vero cell) is a trivalent inactivated vaccine (sIPV) developed by Beijing Minhai Biotechnology (a subsidiary of Shenzhen Kangtai Biological Products) for the prevention of poliomyelitis. The vaccine is derived from attenuated Sabin strains of poliovirus (Types 1, 2, and 3) rather than the wild-type Salk strains, which improves biosafety during the manufacturing process by reducing the risk of environmental reintroduction of virulent virus. It is produced using Vero cell culture technology and inactivated with formaldehyde. This sIPV is designed to provide protective immunity against all three poliovirus serotypes and has been evaluated in Phase I/III clinical trials (e.g., CTR20170982) in infants, children, and adults to support the global transition from oral poliovirus vaccine (OPV) to inactivated poliovirus vaccine (IPV).
- Brand names
- Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains
- Other names
- Sabin-strain IPVsIPV (Vero cell)
Beyond the preview
Go deeper on sabin-strain inactivated poliovirus vaccine (vero cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sabin-strain inactivated poliovirus vaccine (vero cell).